Fulminant post-transplant lymphoproliferative disorder presenting with lactic acidosis and acute liver failure

Nephrology Dialysis Transplantation

Volumn 19, Issue 7, 2004, Pages 1918-1920

  Mathur, Rashmi V ^a   Kudesia, Goura ^a   Suvarna, Kim ^a   McKane, William ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Epstein barr virus; Immunosuppression kidney transplantation; Lymphoma; Post transplant malignancy

Indexed keywords

ACICLOVIR; AMINOTRANSFERASE; AZATHIOPRINE; BICARBONATE; CYCLOSPORIN A; GANCICLOVIR; LYMPHOCYTE ANTIBODY; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALPORT SYNDROME; ARTICLE; AUTOPSY; CASE REPORT; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECG ABNORMALITY; FEVER; GENERAL CONDITION DETERIORATION; HEART INFARCTION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FAILURE; LYMPHOPROLIFERATIVE DISEASE; MALE; METABOLIC ACIDOSIS; MOUTH ULCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR;

ACIDOSIS, LACTIC; HUMANS; KIDNEY TRANSPLANTATION; LIVER FAILURE, ACUTE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED;

EID: 3242674137     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh153     Document Type: Article

References (10)

1. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516
2. Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330-1334
3. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 1413-1421
4. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353
5. Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72: 1783-1786
6. Haque T, Thomas JA, Parratt R, Hunt BJ, Yacoub MH, Crawford DH. A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation 1997; 64: 1028-1034
7. Alfrey EJ, Friedman AL, Grossman RA et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation 1992; 54: 250-253
8. Haque T, Thomas JA, Falk KI et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77: 1169-1172
9. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74: 367-372
10. McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-1611